香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部份內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 本公司股份將繼續暫停買賣，以待達成復牌條件。本公司股東及潛在投資者於買賣本公司股份 時務請審慎行事。 代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 香港，2025 年 8 月 6 日 於本公告日期，本公司董事會包括林品卓先生為執行董事，及樂可慰先生、唐萃環女士及姚 俊榮先生為獨立非執行董事。 董事會召開日期 京玖醫療健康有限公司(「本公司」)董事會宣佈將於 2025 年 8 月 18 日(星期一)舉行董事會會 議，以批准刊發本公司及其附屬公司截至 2025 年 6 月 30 日之未經審核中期業績。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 京玖醫療健康有限公司 | | | 呈交日期: | 2025年8月6日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00648 | 說明 | 京玖康療 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 326,036,828 | | 0 | | 326,036,828 | | 增加 / 減少 (-) | | | 0 ...

復牌之最新資料 本公告乃由本公司根據上市規則第 13.24A 條作出，並提述本公司日期為 2025 年4月30日的公告。 本公告所用之詞彙與該公告所界定者具有相同涵義。 復牌進度更新 聯交所於 2020 年 4 月 21 日知會本公司將暫不行使上市規則第 6.01A(2)(b)(i)條權利將本公司除牌， 惟視乎本公司向證監會呈請之進一步發展情況，可能在其認為適當的情況，於較後階段行使上市 規則第 6.01A 條權利。本公司會繼續解決證監會及聯交所的關注。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部份內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 本公司股份將繼續暫停買賣，以待達成復牌條件。本公司股東及潛在投資者於買賣本公司股份時 務請審慎行事。 代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 香港，2025 年 7 月 31 日 於本公告日期，本公司董事會包括林品卓先生為執行董事，及樂可慰先生、唐萃環女士及姚俊榮 先生為獨立非執行董事。 本集團主要於香港從事分銷醫療及健康設備及產品之醫療及健康 ...

[Business Overview](index=1&type=section&id=%E6%A5%AD%E5%8B%99%E6%A6%82%E8%A6%BD) [Core Business and Market Performance](index=1&type=section&id=%E6%A5%AD%E5%8B%99%E6%A6%82%E8%A6%BD) The Group's core business is distributing medical and health equipment in Hong Kong, achieving revenue growth in FY2024 despite margin pressures - The Group primarily distributes medical and health equipment in Hong Kong as an authorized distributor for seven suppliers, generating revenue from equipment sales, consumables, and support services[4](index=4&type=chunk) - In FY2024, the company recorded a **gain on derecognition of liabilities of HK$328 million**, significantly improving its financial position and achieving a positive net asset value[4](index=4&type=chunk) - The Hong Kong medical device market outlook is positive, with **projected growth of 8.3% in 2025** and a **7.6% CAGR from 2025 to 2030**, presenting growth opportunities for the Group[4](index=4&type=chunk) [Financial Analysis](index=2&type=section&id=%E8%B2%A1%E5%8B%99%E6%A6%82%E8%A6%BD) [Operating Performance](index=2&type=section&id=%E8%B2%A1%E5%8B%99%E6%A6%82%E8%A6%BD) The Group's revenue grew by 6.4% to HK$54.6 million in FY2024, but gross profit and margin declined due to a shift in sales mix FY2023-2024 Operating Performance Comparison | Metric | FY2024 | FY2023 | YoY Change | | :--- | :--- | :--- | :--- | | Revenue (HK$) | 54.6 million | 51.3 million | +6.4% | | Gross Profit (HK$) | 18.4 million | 21.1 million | -12.9% | | Gross Margin | 33.7% | 41.1% | -7.4 p.p. | [Annual Profit Analysis](index=2&type=section&id=%E5%B9%B4%E5%BA%A6%E6%BA%A2%E5%88%A9) The Group's comprehensive profit surged to HK$326.3 million in FY2024, driven by a one-off gain and reduced operating expenses - Annual profit surged to **HK$326.3 million**, primarily due to a **one-off gain of HK$328 million from the derecognition of liabilities**[6](index=6&type=chunk) - Administrative expenses **decreased significantly by 35.1% to HK$9.8 million** due to effective cost controls on staff and office expenses[7](index=7&type=chunk) - Financing costs **plummeted by 89.9% to HK$1.3 million** from HK$12.9 million last year, following the implementation of a debt restructuring plan[8](index=8&type=chunk) [Risks and Other Matters](index=2&type=section&id=%E4%B8%BB%E8%A6%81%E9%A2%A8%E9%9A%AA%E5%8F%8A%E4%B8%8D%E7%A2%BA%E5%AE%9A%E5%9B%A0%E7%B4%A0) [Key Risks and Uncertainties](index=2&type=section&id=%E4%B8%BB%E8%A6%81%E9%A2%A8%E9%9A%AA%E5%8F%8A%E4%B8%8D%E7%A2%BA%E5%AE%9A%E5%9B%A0%E7%B4%A0) The Group faces multiple risks including macroeconomic uncertainties, market competition, supplier dependency, and potential supply chain disruptions - At the macro level, the Group faces risks from **global economic uncertainty, US-China tensions, and inflation**, which could impact the supply chain[9](index=9&type=chunk) - Operational risks include intense market competition eroding margins, **dependency on key suppliers**, failure to renew distribution rights, and inability to adapt to rapid technological changes[9](index=9&type=chunk)[14](index=14&type=chunk) - The company highlights that maintaining a healthy capital structure is crucial for **going concern**, following past financial challenges[9](index=9&type=chunk) [Post-Reporting Period Events and Share Status](index=3&type=section&id=%E5%A0%B1%E5%91%8A%E6%9C%9F%E5%BE%8C%E4%BA%8B%E9%A0%85) No significant events affecting the Group's operations or finances occurred after the reporting period, and its shares remain suspended from trading - No events with a material impact on the Group occurred after the reporting period[11](index=11&type=chunk) - The company's shares will **continue to be suspended from trading**, and shareholders are advised to exercise caution when dealing in the shares[12](index=12&type=chunk)

Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of HKD 54.6 million, an increase from HKD 51.3 million in 2023, while gross profit decreased to HKD 18.4 million from HKD 21.1 million, resulting in a gross margin of 33.7% compared to 41.1% in the previous year[4]. - The net profit attributable to the company's owners surged to HKD 326.3 million from HKD 12.5 million in 2023, primarily due to a one-time gain from debt restructuring[4]. - The group achieved a net cash inflow from operating activities of HKD 3.9 million, a turnaround from a cash outflow of HKD 4.5 million in 2023[5]. - The total borrowings of the group decreased significantly to HKD 33.1 million from HKD 290.8 million in 2023[5]. - The company reported a significant debt restructuring gain of HKD 328,026,000, compared to no such gain in 2023[118]. - Profit before tax surged to HKD 327,954,000 from HKD 14,369,000, marking an increase of 2,283.5%[118]. - Net profit for the year was HKD 326,317,000, compared to HKD 12,511,000 in 2023, reflecting a substantial increase[118]. - Basic and diluted earnings per share improved to HKD 1.0 from HKD 0.038 in the previous year[118]. - The company reported a pre-tax profit of HKD 327,954,000 for 2024, a substantial increase from HKD 14,369,000 in 2023, reflecting a growth of 2,183%[121]. Assets and Liabilities - As of December 31, 2024, the total assets and net assets of the group were HKD 54.7 million and HKD 2.5 million, respectively, with cash and bank balances of HKD 8.8 million, up from HKD 8.1 million in 2023[5]. - The total assets for the group as of December 31, 2024, amounted to HKD 54,667,000, compared to HKD 56,073,000 in 2023, reflecting a decrease of approximately 2.3%[175]. - The group’s total liabilities as of December 31, 2024, were HKD 52,211,000, a decrease from HKD 379,934,000 in 2023, indicating a significant reduction in liabilities[175]. - The company reported a net asset value of HKD 2,456,000, recovering from a net liability of HKD 323,861,000 in 2023[119]. - Cash and cash equivalents at the end of 2024 increased to HKD 8,773,000 from HKD 8,068,000 in 2023, marking a rise of 8.7%[121]. Corporate Governance - The company has maintained compliance with applicable corporate governance codes and regulations throughout the fiscal year ending December 31, 2024[50][57]. - The audit committee, composed of three independent non-executive directors, reviewed the financial statements and found no discrepancies with the auditors[51]. - The company has adopted a board diversity policy that considers factors such as gender, culture, education background, professional experience, skills, knowledge, and tenure for board appointments and re-elections[60]. - All directors are required to retire and stand for re-election every 3 years at the annual general meeting, ensuring a rotation of board members[61]. - The board has established four committees, each with independent authority, to enhance governance and oversight[64]. Employee and Social Responsibility - The group had 19 employees as of December 31, 2024, down from 22 in 2023, with compensation determined based on performance and market conditions[49]. - The company has implemented measures to enhance employee health and safety in response to the COVID-19 pandemic, including regular disinfection of the workplace[96]. - The company has a commitment to training and development, providing comprehensive on-the-job training programs and encouraging participation in external seminars[97]. - The company adheres to labor standards, strictly prohibiting child labor and forced labor, with no serious violations reported during the year[98]. - The company has established a mandatory MPF retirement benefit plan for eligible employees, with contributions calculated as a percentage of basic salary[160]. Environmental, Social, and Governance (ESG) - The company has set up an Environmental, Social, and Governance (ESG) committee to enhance awareness of ESG matters across the group[78]. - The company complies with the Air Pollution Control Ordinance, Wastewater Treatment Ordinance, and Water Pollution Ordinance without any violations reported[84]. - The company has conducted a materiality assessment to identify significant ESG issues relevant to its business and stakeholders[82]. - The company emphasizes the importance of sustainable development and resource conservation in its operations[77]. - The group is committed to sustainable development and aims to create long-term value for society and stakeholders by incorporating environmental factors into its decision-making process[104]. Revenue and Customer Relations - The largest customer accounted for 8.7% of the group's revenue, while the top five customers represented 29.5%[26]. - The largest supplier constituted 42.6% of the group's procurement, with the top five suppliers making up 95.3%[26]. - The group emphasizes the importance of product and service quality as a key competitive advantage, ensuring customer satisfaction through comprehensive training for all service personnel[100]. - The group has not identified any serious violations of laws and regulations related to health and safety, advertising, labeling, and privacy concerning the products and services provided during the year[100]. Financial Reporting and Compliance - The company has adopted accounting policies and applied them consistently to prepare fair and true consolidated financial statements[73]. - The company has not applied any new or revised Hong Kong Financial Reporting Standards that would have a significant impact on its financial position or performance for the current and prior years[124]. - The group assesses tax implications of transactions and records corresponding tax provisions regularly[168]. - The company has confirmed compliance with the standard code for securities trading by all directors for the year ending December 31, 2024[71]. Future Outlook and Strategy - The company plans to focus on organic growth through improved business models, increased market penetration, and product range expansion despite ongoing economic challenges[7]. - The company has no specific major investment or capital asset acquisition plans as of the report date but will continue to seek appropriate investment opportunities[10]. - The group has no significant events occurring after the reporting date[31].

Financial Performance - For the year ended December 31, 2024, the company reported total revenue of HKD 54,639,000, an increase of 6.4% from HKD 51,340,000 in 2023[3] - The cost of goods sold for 2024 was HKD 36,241,000, compared to HKD 30,215,000 in 2023, resulting in a gross profit of HKD 18,398,000, down 13.0% from HKD 21,125,000[3] - The net profit for the year was HKD 326,317,000, a significant increase from HKD 12,511,000 in 2023[3] - Basic and diluted earnings per share for 2024 were HKD 1.00, compared to HKD 0.038 in 2023[3] - Gross profit for the year was HKD 184 million, down from HKD 211 million in 2023, resulting in a gross margin of 33.7%, compared to 41.1% in the previous year[30] - The net profit attributable to the company's owners was HKD 326.3 million, significantly up from HKD 12.5 million in 2023, primarily due to a one-time gain from debt restructuring[30] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 49,812,000, up from HKD 35,098,000 in 2023[4] - The company reported a net asset value of HKD 2,456,000 in 2024, a recovery from a net liability of HKD 323,861,000 in 2023[4] - The total liabilities of the group as of December 31, 2024, were HKD 52,211,000, with reported segment liabilities of HKD 31,703,000[15] - As of December 31, 2024, total assets were valued at HKD 547 million, a decrease from HKD 561 million in 2023, while net assets were HKD 25 million, compared to a net liability of HKD 323.9 million in 2023[31] - The total borrowings amounted to HKD 33.1 million, down from HKD 290.8 million in 2023, which included HKD 230 million in loans and HKD 60.8 million in bonds payable[31] Operational Highlights - Inventory increased to HKD 4,781,000 in 2024 from HKD 2,830,000 in 2023, indicating a growth of 68.8%[4] - Trade receivables rose significantly to HKD 16,739,000 in 2024 from HKD 7,108,000 in 2023, marking an increase of 135.5%[4] - The adjusted profit before tax for the medical and health segment was HKD 12,265,000 for 2024, compared to HKD 11,308,000 in 2023, reflecting an increase of 8.5%[15] - The average credit period for trade receivables remained at 90 days, with trade receivables increasing to HKD 16.7 million in 2024 from HKD 7.1 million in 2023[25] Debt and Financing - The company recognized a debt restructuring gain of HKD 328,026,000 in 2024, which was not present in 2023[3] - The company incurred financing costs of HKD 1,321,000 in 2024, a significant decrease from HKD 12,940,000 in 2023, indicating improved financial management[19] - The company has no outstanding bonds as of 2024, compared to HKD 60.8 million in 2023[26] Governance and Risk Management - The company has adopted a set of corporate governance principles and practices to ensure effective risk management and internal control systems[39] - A Risk Management Committee was established in April 2023, consisting of two independent non-executive directors and one executive director, to continuously review and monitor the effectiveness of risk management and internal control systems[39] - The Audit Committee has reviewed the group's annual performance for the year ending December 31, 2024, including the accounting principles and practices adopted by the group[41] - The auditors confirmed that the preliminary announcement aligns with the audited consolidated financial statements approved by the board on March 25, 2025[42] Future Outlook - The group plans to focus on improving business models, increasing market penetration, and expanding product ranges to achieve organic growth despite ongoing economic challenges[33] - No capital raising activities were completed during the year ending December 31, 2024[34] - The company will publish its 2024 annual report, which will be sent to shareholders and made available on the company's and the stock exchange's websites[43]

Financial Performance - The company recorded revenue of HKD 30.7 million for the six months ended June 30, 2024, compared to HKD 20.6 million in 2023, representing a growth of 48.8%[3] - Gross profit for the same period was HKD 10.8 million, with a gross margin of 35.1%, down from HKD 11.4 million and 55.3% in 2023[3] - The consolidated loss attributable to the company was HKD 6.1 million, an increase from HKD 3.4 million in 2023, primarily due to fair value losses on financial assets[3] - Revenue for the six months ended June 30, 2024, was HKD 30,704,000, an increase of 49.1% compared to HKD 20,599,000 for the same period in 2023[18] - Gross profit for the same period was HKD 10,790,000, a decrease of 5.3% from HKD 11,393,000 in 2023[18] - The company reported a loss before tax of HKD 4,793,000 for the six months ended June 30, 2024, compared to a loss of HKD 2,658,000 in 2023[18] - Total comprehensive loss for the period was HKD 6,093,000, compared to a loss of HKD 3,401,000 in the previous year[18] - The company reported a net cash outflow from operating activities of HK$11,513,000 for the six months ended June 30, 2024, compared to HK$5,109,000 in the same period of 2023[22] - The company recorded a loss before tax of HK$4,793,000 for the six months ended June 30, 2024, compared to a profit of HK$7,995,000 in the same period of 2023[27] - The company reported a basic and diluted loss per share of HK$0.0187 for the six months ended June 30, 2024, compared to HK$0.0119 in the same period of 2023[36] Assets and Liabilities - As of June 30, 2024, total assets were HKD 50.1 million, down from HKD 56.1 million at the end of 2023, while total liabilities increased to HKD 330.0 million from HKD 323.9 million[4] - The company had a cash and bank balance of HKD 4.1 million, a decrease from HKD 8.1 million at the end of 2023[4] - Non-current assets as of June 30, 2024, totaled HKD 9,278,000, a decrease from HKD 20,975,000 as of December 31, 2023[20] - Current assets increased to HKD 40,854,000 as of June 30, 2024, compared to HKD 35,098,000 at the end of 2023[20] - Current liabilities amounted to HKD 380,086,000 as of June 30, 2024, slightly up from HKD 376,688,000 at the end of 2023[20] - The company had a net current liability of HK$339.2 million and a net liability of HK$330.0 million as of June 30, 2024, raising significant doubts about its ability to continue as a going concern[24] - Total borrowings as of June 30, 2024, were HKD 234,520,000, up from HKD 229,985,000 as of December 31, 2023, indicating a 2% increase[40] - The company has issued bonds totaling HKD 60,818,000 due within one year, unchanged from December 31, 2023[41] - The company’s total borrowings include principal amounts of HKD 200,900,000, with interest rates ranging from 2% to 8.5%[40] Operational Insights - The company plans to focus on improving business models, increasing market penetration, and expanding product range to achieve organic growth despite economic challenges[5] - No significant capital raising activities or major investments were completed in the six months ended June 30, 2024[6] - The company continues to monitor foreign exchange risks closely, as its operations are primarily denominated in HKD[7] - The company has successfully implemented measures to alleviate uncertainties regarding its going concern status, including extending a loan repayment date by six months[24] - The company successfully implemented a plan to distribute cash to creditors as of the report date[43] - An agreement was made to extend the maturity date of a HKD 15,000,000 loan by six months to March 31, 2025[43] Employee and Governance - The company has 21 employees as of June 30, 2024, down from 22 at the end of 2023[8] - The company is committed to maintaining high standards of corporate governance, having complied with the relevant codes during the reporting period[16] Trade and Receivables - Trade receivables as of June 30, 2024, amounted to HKD 9,087,000, compared to HKD 7,108,000 as of December 31, 2023, representing a 28% increase[38] - The aging analysis of trade receivables shows that amounts overdue by 0-30 days increased from HKD 506,000 to HKD 950,000, a rise of 88%[38] - Trade payables as of June 30, 2024, totaled HKD 2,190,000, with no previous amounts reported as of December 31, 2023[39] Other Financial Metrics - The company incurred total depreciation expenses of HK$427,000 for the six months ended June 30, 2024, down from HK$662,000 in the same period of 2023[34] - Interest income from bank balances was nil for the six months ended June 30, 2024, compared to HK$153,000 in the same period of 2023[31] - The company did not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous year[35] - Total equity attributable to owners was HKD (329,954,000) as of June 30, 2024, compared to HKD (323,861,000) at the end of 2023[21]

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 30,704,000, an increase of 49% compared to HKD 20,599,000 for the same period in 2023[7] - Gross profit for the period was HKD 10,790,000, down from HKD 11,393,000 in the previous year, reflecting a decrease of approximately 5.3%[1] - The company reported a loss before tax of HKD 4,793,000, compared to a loss of HKD 2,658,000 in the same period last year, indicating a worsening of 80%[1] - Total comprehensive loss for the period was HKD 6,093,000, compared to HKD 3,401,000 in the previous year, representing an increase of 79.3%[1] - The company reported a loss attributable to owners of the company of HKD 6,093,000 for the six months ended June 30, 2024, compared to HKD 3,874,000 for the same period in 2023[15] - The consolidated loss attributable to the company was HKD 6.1 million, an increase from HKD 3.4 million in 2023, primarily due to fair value losses on financial assets[22] Assets and Liabilities - Current liabilities net amount was HKD 339,232,000, slightly improved from HKD 341,590,000 in the previous period[4] - Non-current assets, including property, plant, and equipment, increased to HKD 2,584,000 compared to HKD 238,000 at the end of 2023[2] - The total assets less current liabilities amounted to HKD 329,954,000, compared to HKD 320,615,000 in the previous period, showing a slight increase[4] - As of June 30, 2024, total assets amounted to HKD 50,132,000, with segment assets in the medical and health business at HKD 44,258,000[10] - The company’s total liabilities as of June 30, 2024, were HKD 380,086,000, with segment liabilities in the medical and health business at HKD 26,661,000[10] - As of June 30, 2024, total assets were HKD 50.1 million, down from HKD 56.1 million as of December 31, 2023, while total liabilities increased to HKD 330.0 million from HKD 323.9 million[23] Cash Flow and Financing - The net cash outflow from operating activities was HKD 11.4 million for the six months ended June 30, 2024, compared to HKD 9.0 million in 2023[23] - The group had a cash and bank balance of HKD 4.1 million as of June 30, 2024, down from HKD 8.1 million as of December 31, 2023[23] - The total borrowings amounted to HKD 295.3 million as of June 30, 2024, compared to HKD 290.8 million as of December 31, 2023[23] - The company has extended the maturity of a HKD 15,000,000 loan by six months to March 31, 2025, to improve liquidity[6] - The company has successfully implemented a plan to extend a loan of HKD 15,000,000 by six months to March 31, 2025[20] Business Operations - The company continues to develop its medical and health business to enhance its financial position[6] - For the six months ended June 30, 2024, the company reported external sales of HKD 20,599,000 in the medical and health business, with a total segment profit of HKD 7,995,000[10] - The company incurred a pre-tax loss of HKD 2,658,000 after allocating unallocated corporate expenses and financing costs of HKD 4,829,000 and HKD 5,824,000 respectively[10] - Future business operations may be impacted by ongoing global economic challenges, but the company aims to improve business models and expand product offerings for organic growth[24] Corporate Governance - The company confirmed compliance with the standard code for securities trading by all directors for the six months ended June 30, 2024[37] - The company is committed to maintaining high levels of corporate governance and has adhered to the corporate governance code provisions, except for the vacancy in the CEO position[38] - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the six months ended June 30, 2024, which were not audited by the company's auditor but deemed compliant with applicable accounting standards[39] Share Incentive Plan - The company adopted a share incentive plan on June 19, 2015, with a duration of 10 years to recognize contributions from eligible participants[36] - As of June 30, 2024, the company has not granted any share incentives to any individuals under the share incentive plan[36] Dividends - The company did not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous year[14] Costs and Expenses - The company recognized a cost of goods sold of HKD 19,914,000, significantly higher than HKD 9,206,000 in the previous year[13] - Interest income from bank balances was reported at HKD 0 for the six months ended June 30, 2024, down from HKD 153,000 in 2023[11] Capital Commitments - The group had no significant capital commitments or contingent liabilities as of June 30, 2024[28]

Financial Performance - The company recorded revenue of HKD 51.3 million for the year ending December 31, 2023, compared to HKD 33.8 million in 2022, representing a growth of 51.5%[3]. - Gross profit for the year was HKD 21.1 million, with a gross margin of 41.1%, up from HKD 13.7 million and a gross margin of 40.5% in 2022[3]. - The company achieved a net profit of HKD 12.5 million in 2023, a significant turnaround from a loss of HKD 19.2 million in 2022[3]. - Total revenue for 2023 was HKD 51,340,000, an increase of 52.1% compared to HKD 33,765,000 in 2022[130]. - Gross profit for 2023 was HKD 21,125,000, up 54.0% from HKD 13,737,000 in 2022[130]. - The net profit for 2023 was HKD 12,511,000, a significant recovery from a loss of HKD 19,225,000 in 2022[130]. - The company reported a basic and diluted earnings per share of HKD 0.038, compared to a loss per share of HKD 0.059 in the previous year[130]. - The group recorded a pre-tax profit of HKD 14,369,000 for 2023, compared to a pre-tax loss of HKD 16,632,000 in 2022, marking a turnaround in performance[196]. Cash Flow and Liquidity - Cash and bank balances increased to HKD 8.1 million in 2023 from HKD 3.1 million in 2022, indicating improved liquidity[4]. - The company reported a net cash inflow of HKD 5.0 million for the year, compared to a cash outflow of HKD 0.6 million in 2022[5]. - The cash flow from operating activities showed a net outflow of HKD 4,490,000 in 2023, an increase in outflow compared to HKD 2,843,000 in 2022[135]. - The company’s cash and cash equivalents increased to HKD 8,068,000 at the end of 2023, compared to HKD 3,096,000 at the beginning of the year[135]. Assets and Liabilities - The total assets of the company were HKD 56.1 million as of December 31, 2023, compared to HKD 24.6 million in 2022, showing a substantial increase[4]. - The group’s total liabilities as of December 31, 2023, were HKD 379,934,000, compared to HKD 368,595,000 in 2022, showing a slight increase of 3.6%[196]. - The company reported a net current liability of approximately HKD 341,590,000 and a net liability of approximately HKD 323,861,000 as of December 31, 2023[118]. - The company’s total equity attributable to owners was a loss of HKD 323,861,000, improving from a loss of HKD 336,372,000 in 2022[132]. Borrowings and Debt Management - The company’s total borrowings amounted to HKD 290.8 million in 2023, up from HKD 275.6 million in 2022[4]. - The company raised new loans amounting to HKD 13,526,000 in 2023, up from HKD 7,243,000 in the previous year[135]. - The company has entered into a loan agreement with investors for up to HKD 8 million, fully drawn as of December 31, 2023, and a second loan agreement for up to HKD 10 million to settle creditor claims[147]. - A debt restructuring plan is in place, with an estimated HKD 345 million in debt expected to be fully and finally discharged after the settlement payment, which will range from HKD 8.6 million to HKD 10.4 million depending on creditor choices[147]. Corporate Governance - The board of directors confirmed the independence of all independent non-executive directors according to the listing rules[34]. - The company has adopted a board diversity policy in line with corporate governance code provisions, considering various factors for board appointments[62]. - The board of directors has established four committees, each with independent authority[67]. - The Audit Committee held three meetings during the year, with all members in attendance, and reviewed the interim and annual performance for the year ending December 31, 2023[68]. Environmental, Social, and Governance (ESG) Initiatives - The company has set up an Environmental, Social, and Governance (ESG) committee to enhance awareness of ESG matters across the group[84]. - The company reported greenhouse gas emissions of 29.8 tons (CO2 equivalent) for the year, an increase from 26.4 tons in the previous year[94]. - The group has implemented measures to monitor and mitigate the environmental impact of its operations, integrating environmental considerations into future strategic planning[97]. - The group has established policies to enhance operational resilience against extreme weather events, including typhoons and heavy rain[98]. Employee and Labor Practices - The group had 22 employees as of December 31, 2023, with compensation determined based on performance, experience, and current market conditions[51]. - The gender distribution of employees as of December 31, 2023, was 64% male and 36% female, with age groups showing 23% aged 20-35, 36% aged 36-50, and 41% aged 51 and above[104]. - The group emphasizes employee training and development, providing comprehensive on-the-job training programs and encouraging participation in external seminars[106]. - The group adheres to fair recruitment practices and regularly reviews compensation and benefits policies based on market standards[103]. Risk Management - The company has identified significant risks related to fraud and errors in financial reporting, emphasizing the importance of internal controls[127]. - The Risk Management Committee was established in April 2023 to continuously review and monitor the effectiveness of risk management and internal control systems[73]. Revenue Recognition and Accounting Policies - Revenue is recognized at the amount the group expects to receive in exchange for goods or services, net of VAT or other sales taxes[172]. - The group recognizes provisions for liabilities when there is a legal or constructive obligation that may result in an outflow of economic benefits[183]. - Financial assets are initially measured at fair value plus transaction costs, except for trade receivables without significant financing components, which are measured at transaction price[159].

Financial Performance - The company reported a revenue of HKD 51,340,000 for the year ended December 31, 2023, representing a 52.1% increase from HKD 33,765,000 in 2022[5] - Gross profit for the year was HKD 21,125,000, up 54.0% from HKD 13,737,000 in the previous year[5] - The company achieved a net profit of HKD 12,511,000 for the year, compared to a net loss of HKD 19,225,000 in 2022[5] - Revenue from the distribution of medical equipment and products increased to HKD 51,340,000 in 2023, up 52.1% from HKD 33,765,000 in 2022[15] - The company's adjusted profit before tax for the medical and health business segment was HKD 11,308,000 in 2023, compared to HKD 6,834,000 in 2022, representing a 65.5% increase[19] - The group recorded revenue of HKD 513 million for the year ending December 31, 2023, compared to HKD 338 million in 2022, representing a growth of approximately 51.8%[33] - Gross profit for the same period was HKD 211 million, up from HKD 137 million in 2022, resulting in a gross margin of 41.1%, compared to 40.5% in the previous year[33] Assets and Liabilities - The company's total assets increased to HKD 35,098,000 in 2023 from HKD 18,605,000 in 2022, reflecting an increase of 88.5%[6] - Total assets as of December 31, 2023, amounted to HKD 56,073,000, an increase from HKD 24,640,000 in 2022[19] - The total assets of the group reached HKD 561 million in 2023, compared to HKD 246 million in 2022, indicating substantial growth in asset value[34] - The company's total liabilities as of December 31, 2023, were HKD 379,934,000, compared to HKD 368,595,000 in 2022, indicating a slight increase[19] - As of December 31, 2023, the company reported current liabilities of approximately HKD 341,590,000 and total liabilities of HKD 323,861,000[46] - The company's cash and cash equivalents were only about HKD 8,068,000, while borrowings and bonds payable totaled HKD 287,557,000[46] - Approximately HKD 262,735,000 of borrowings and bonds payable were overdue as of December 31, 2023, raising significant doubts about the company's ability to continue as a going concern[46] Expenses and Costs - The company reported a significant reduction in administrative expenses, which fell to HKD 15,087,000 from HKD 23,021,000, a decrease of 34.6%[5] - Financing costs decreased to HKD 12,940,000 in 2023 from HKD 15,549,000 in 2022, reflecting a reduction of 16.5%[22] - Depreciation expenses for property, plant, and equipment were HKD 1,189,000 in 2023, a decrease from HKD 2,040,000 in 2022[24] - Other income, including bank interest and foreign exchange gains, totaled HKD 6,921,000 in 2023, down from HKD 9,765,000 in 2022[21] Corporate Governance and Future Outlook - The company has engaged in a debt restructuring plan to restore its financial and operational status, with an estimated HKD 345 million of debt expected to be fully and finally discharged[9] - The company has been continuously developing its healthcare business to improve operational cash flow[9] - The company expects that the newly issued Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements in the foreseeable future[14] - The company has adopted a new corporate governance framework emphasizing effective risk management and internal control systems[42] - The group aims to expand its existing business and seek new commercial opportunities despite ongoing global economic challenges[36] Shareholder Information - The company did not declare any dividends for the year ending December 31, 2023, consistent with the previous year[25] - The total issued shares remained unchanged at 326,037,000 shares, with a total issued capital of HKD 3,030.66 million[35] - The company is under a trading suspension since November 27, 2017, and is working towards meeting the resumption conditions set by the stock exchange[36] Cash Flow - Cash and cash equivalents increased to HKD 8,068,000 in 2023 from HKD 3,096,000 in 2022, marking a 160.5% increase[6] - The group's net cash inflow for the year was HKD 5.0 million, a turnaround from a net outflow of HKD 0.6 million in 2022[34] Trade Receivables - Trade receivables rose significantly to HKD 7.1 million in 2023 from HKD 1.0 million in 2022, with a notable increase in receivables aged 31 to 90 days[28] Audit and Review - The audit committee has reviewed the annual performance for the year ending December 31, 2023, ensuring alignment with the consolidated financial report[47]